.
One approach for studying drugs with atypical mechanisms of action is drug discrimination, largely because of its pharmacological selectivity (Shannon and Holtzman, 1976; Mansbach and Balster, 1991; Terry et al., 1994) . Among the small number of studies in the literature on this topic, a range of conditions (gender, strain, reinforcer, task, dose, and route) have been used to study the discriminative stimulus effects of GHB. For example, female CFN-strain rats responded for water (Winter, 1981) whereas male Long-Evans rats traversed a T-maze for food (Colombo et al., 1995; Colombo et al., 1998) ; smaller doses (i.p.) were studied in the former, larger doses (i.g.) in the latter. Previous studies in rats (Winter, 1981; Colombo et al., 1995; Colombo et al., 1998; Metcalf et al., 2001 ) and pigeons (CPF, unpublished observation) discriminating GHB have implicated GABA receptors in the discriminative effects of GHB. In rats discriminating 200 mg/kg GHB i.p. (Winter, 1981) the GABAergic compounds baclofen, muscimol, and chlordiazepoxide occasioned GHB-appropriate responding whereas the nonGABAergic compounds PCP, lysergic acid diethylamide, damphetamine, and apomorphine did not. In rats discriminating 300 or 700 mg/kg GHB i.g. (Colombo et al., 1998 ) the GABAergic compounds baclofen and diazepam occasioned GHB-appropriate responding whereas dizocilpine and WIN 55,212-2 did not.
The first goal of this study was to confirm and extend results from other laboratories, with a more widely-used two-lever, fixed-ratio (FR) schedule of responding for food.
Evaluation of compounds under these conditions should facilitate interpretation of the results within the context of a drug discrimination literature that is largely founded on this procedure. Second, although GABA is clearly important in the behavioral actions of GHB, several important issues are unresolved, including the relative importance of GHB receptors in the GHB discriminative stimulus. Thus, a second goal of this study was to examine the role of GABA and other receptors in the GHB discriminative stimulus by examining receptor-selective agonists and antagonists in combination. This is particularly important for GHB receptors since antagonism of GHB is not unanimously obtained with NCS-382. A third goal was to characterize two metabolic precursors of GHB, 1,4-butanediol (1,4-BDL) and γ-butyrolactone (GBL); 1,4-BDL is reported to be used by GHB abusers, although the relative interchangeability of these compounds has not been studied.
Rats discriminating 200 mg/kg GHB were used to evaluate the following:
metabolic precursors 1,4-BDL and GBL; GABA A agonist muscimol; GABA A positive modulators diazepam, pentobarbital, and pregnanolone; GABA B agonist baclofen; µ-opioid agonist morphine; NMDA antagonist ketamine; and the purported GHB antagonist NCS-382. Time course was determined for GHB, 1,4-BDL, and GBL. The benzodiazepine antagonist flumazenil, GABA B antagonist CGP 35348, and GHB-site antagonist NCS-382 were studied in combination with GHB and with other pharmacologically-relevant compounds.
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Operant chambers
For daily sessions animals were transported from the colony room to an adjacent room supplied with white noise. Experimental sessions were conducted in soundattenuating, well-ventilated enclosures (Model # ENV-022M and ENV-008CT; MED Associates Inc., St. Albans, VT), which contained an operant chamber of which 3 sides This article has not been copyedited and formatted. The final version may differ from this version. delivered from a food hopper external to the operant chamber, but within the enclosure.
Data were collected using MED-PC IV software (MED Associates, St. Albans, VT) and a PC interface.
Experimental sessions
Rats were trained to discriminate 200 mg/kg GHB from saline using a two-lever, food-reinforced procedure under a FR schedule. Discrimination training began after the animal received 100 food pellets on either the right or the left lever under a concurrent schedule of continuous reinforcement. In subsequent sessions the response requirement was systematically increased (by 1 or 2) to 10, a pretreatment (PT) period was introduced, and the duration of daily sessions was shortened from 60 min to 15 min.
Terminal training sessions consisted of a 15 min PT period, during which the operant chamber was dark and responses had no programmed consequence, followed by a 15 min response period, in which the lights above both levers were illuminated and 10 responses immediately prior to the 15 min PT determined whether responding on the right or left lever was reinforced; injection volumes were between 0.28 and 2.5 ml/kg. The lever that resulted in food pellet delivery following an injection of GHB was counterbalanced across subjects so that responding on the right lever was reinforced for 4 animals and on the left lever for the other 4 animals following the training dose of GHB. Experimental sessions were conducted 7 days a week and the order of training sessions was generally double alternation (e.g. drug, drug, saline, saline, etc.)
Criteria for determining whether an animal was under adequate stimulus control for testing were as follows: at least 90% of the total responses on the injectionappropriate lever and fewer than 10 responses on the incorrect lever prior to the delivery of the first reinforcer. Initially, for each animal these criteria had to be satisfied for 5
consecutive days, or 6 out of 7 days with at least 2 drug and 2 saline training days. After these initial criteria were satisfied, animals were required to meet criteria for at least one saline and one drug training day in 2 of the 3 days prior to a test (including the day immediately prior to the test). Test sessions were identical to training sessions with the exception that completion of the FR on either lever resulted in food pellet delivery. Two or three tests were conducted weekly in each subject, depending on performance during intervening training sessions; drugs were studied using a single dosing procedure. On days during which time course data were obtained, the response period was shortened to than 15 min the animal was returned to its home cage after administration of the test compound and placed in the operant chamber 15 min prior to the scheduled response period. All antagonists were administered 10 min prior to a test compound. NCS-382 (sodium salt), and CGP 35348 (sodium salt). NCS-382 and CGP 35348 were synthesized as previously described (Maitre et al., 1990; Froestl et al., 1995) . Diazepam was dissolved in vehicle consisting of 70% emulphor, 20% sterile water, and 10% ethanol (by volume). Pregnanolone was dissolved in 45% γ-cyclodextrin (Sigma-Aldrich) in sterile water. Flumazenil was dissolved in vehicle consisting of 50% saline, 40%
Drugs
propylene glycol, and 10% ethanol (by volume). Doses are expressed as the weight of the free base, except where indicated otherwise.
Data analysis
The percentage of responses on the GHB lever during the response period is plotted as drug-appropriate responding (%DR). Rate of lever pressing on both levers is This article has not been copyedited and formatted. The final version may differ from this version. 
Results

GHB discrimination
The median number of days to meet testing criteria was 35 (range: 23-41). GHB occasioned dose-dependent increases in drug-appropriate responding up to doses that significantly decreased rate of responding (Fig. 1) . Following the training dose of 200 mg/kg GHB, an average of 83.1 ± 12.6% drug-appropriate responding was observed.
GHB precursors 1,4-BDL and GBL occasioned dose-dependent increases in GHB lever responding up to doses that significantly decreased rates of responding ( Fig. 1) . Doses of 178 and 320 mg/kg 1,4-BDL occasioned 77.4 ± 14.6% and 89.7 ± 7.9% GHB-appropriate responding, respectively. The largest dose of 1,4-BDL tested (320 mg/kg) decreased rate of responding to 43.1% of the vehicle control rate. In contrast, GBL elicited a maximum average of 49.8% drug-appropriate responding, but only at a dose that decreased the rate of responding to 14.4% of the vehicle control rate (Fig. 1 ).
The GABA B agonist baclofen dose-dependently increased GHB-lever responding up to doses that markedly decreased rates of responding (Fig. 2) . Baclofen occasioned 84.1 ± 13.1% drug-appropriate responding at a dose of 3.2 mg/kg. A dose of 5.6 mg/kg baclofen decreased rate of responding to less than 10% of the vehicle control rate (Fig.   2 ).
GABA A positive modulators diazepam and pregnanolone dose-dependently increased GHB-lever responding up to doses that markedly decreased rates of responding (Fig. 2) . Diazepam occasioned 65.9 ± 17.3% drug-appropriate responding at a dose of 3.2 mg/kg. Pregnanolone elicited 28.4 ± 23.9% drug lever responding at 5.6 mg/kg. (Fig. 2) . The GABA A direct-acting agonist muscimol and barbiturate-site positive modulator pentobarbital did not occasion greater than 17% GHB-appropriate responding at any dose tested, up to doses that markedly decreased rate of responding (Table 1) .
Morphine and ketamine occasioned less than 40% drug-appropriate responding up to doses that decreased rate of responding (Table 1) . Doses of 1.0 and 3.2 mg/kg of morphine occasioned 37.1 ± 18.1% and 36.9 ± 20.7% drug-appropriate responding.
Ketamine elicited 35.4 ± 17.3% and 32.2 ± 16.3% drug-appropriate responding at 1.0 and 3.2 mg/kg. Both morphine and ketamine decreased rate of responding to less than 16% of the vehicle control rate at 10 mg/kg (Table 1) .
Time course studies
Discriminative stimulus effects of GHB were evident 15 min after administration (Fig. 3) . At 30 min post-injection, the discriminative stimulus effects of 200 mg/kg GHB were still present as evidenced by 74.1 ± 18.6% drug-appropriate responding. However, 60 min after administration of 200 mg/kg GHB, drug lever responding was similar to that observed with vehicle (Fig. 3) . 1,4-BDL exhibited a longer duration of action than GHB, as evidenced by substantial drug-appropriate responding 60 and 90 min after administration (99.3 ± 0.3% and 40.7 ± 17.8%, respectively; Fig. 3 ). The largest dose of GBL that did not decrease responding (32 mg/kg) did not occasion greater than 40%
GHB-appropriate responding when longer pretreatment intervals were used (upper panel, Fig. 3 ).
Antagonism studies
The purported GHB antagonist NCS-382 in combination with 200 mg/kg GHB decreased drug-appropriate responding from 83.1 ± 12.6% (control) to 38.0 ± 16.9% at a dose of 32 mg/kg NCS-382 (Fig. 4) . Doses of 10 and 32 mg/kg NCS-382 also attenuated the modest rate decreasing effects of 200 mg/kg GHB. At 56 and 100 mg/kg NCS-382 (in combination with GHB), drug-appropriate responding and rate of responding were not markedly different than with 200 mg/kg GHB alone (Fig. 4) . When administered alone NCS-382 occasioned substantial responding on the GHB lever (56 and 100 mg/kg) and dose-dependently decreased rate of responding ( Fig. 4 and Table 1 ). A maximum of 49.5
± 19.1% drug-appropriate responding was obtained with 100 mg/kg NCS-382.
GHB-lever responding occasioned by diazepam was dose-dependently attenuated by the benzodiazepine-site antagonist flumazenil (Fig. 5) . In contrast, the same doses of flumazenil failed to antagonize the discriminative stimulus effects of 200 mg/kg GHB (closed symbols, upper panel, Fig. 5 ). Pretreatment with 5.6 mg/kg flumazenil decreased drug-appropriate responding occasioned by diazepam to less than 20% of control; the same dose of flumazenil had no clear effect on the discriminative stimulus effects of GHB. Rate-decreasing effects of GHB and diazepam were less when these drugs were studied in combination with flumazenil.
Baclofen elicited GHB-lever responding that was antagonized by the GABA B receptor antagonist CGP 35348 (Fig. 6) . The same doses of CGP 35348 that attenuated GHB-appropriate responding occasioned by baclofen also dose-dependently antagonized the discriminative stimulus effects of the training dose of GHB (Fig. 6) 
Discussion
With reports of increased recreational use of GHB as well as the recent marketing of GHB for the treatment of narcolepsy there has been a renewed interest in understanding the mechanism(s) by which this molecule exerts abuse-related and therapeutic effects. Since its isolation, much has been learned about GHB, although the mechanisms that mediate the behavioral actions of GHB are not fully described. Among the many procedures that have been used to study GHB is drug discrimination, a procedure that has a high degree of pharmacologic specificity. Previous discrimination studies with GHB in rats (Winter, 1981; Colombo et al., 1995; Colombo et al., 1998; Metcalf et al., 2001 ) suggested a role for GABAergic mechanisms; however, the extent to which GABA or other receptors mediate these effects of GHB and the extent to which other metabolically related compounds share effects with GHB was not fully explored.
The current study established stimulus control with GHB in rats responding under conditions that have been used widely in drug discrimination research (two-lever, FR, food-maintained responding); for compounds that were studied in both the current procedure and with other procedures, substitution data appear relatively consistent across different subjects, doses, routes of administration, gender, strain, and reinforcer.
Moreover, the time required to establish stimulus control was similar to what has been reported for drug discrimination in rats with GHB or other drugs (Winter, 1981; Engel et al., 2001 ).
Abuse of other GHB-related compounds has reportedly increased, perhaps, because GHB was designated Schedule-I (Mason and Kerns, 2002) . This study provides clear evidence that one of these metabolic precursors of GHB, 1,4-BDL, shares
This article has not been copyedited and formatted. The final version may differ from this version. (Roth and Giarman, 1968; Benavides et al., 1982; Snead and Liu, 1984; Carter et al., 2002) , an hypothesis that is consistent with the similar discriminative stimulus effects of these two compounds in rats as well as reports of 1,4-BDL use by human GHB abusers (Mason and Kerns, 2002) . Discriminative stimulus effects of GHB were evident 15 min after administration whereas an equi-effective dose of 1,4-BDL produced comparable effects 30-90 min after administration. The comparatively longer time course of 1,4-BDL is also consistent with 1,4-BDL being converted to GHB (Roth and Giarman, 1968; Maxwell and Roth, 1972; Snead et al., 1989) . The longer duration of action of 1,4-BDL could be preferable in future studies with chronic dosing.
1,4-BDL and GBL are metabolized to GHB by different enzymes (alcohol dehydrogenase and peripheral lactonases, respectively); thus, differences in pharmacokinetics and distribution of enzymes could account for the comparatively smaller effect obtained with GBL Maxwell and Roth, 1972; Gold and Roth, 1977; Snead et al., 1989) . The limited effects that were obtained in this study with GBL, as well as with morphine and ketamine, are consistent with effects of the same or similar (PCP) drugs in female rats discriminating the same dose of GHB while under other conditions (Winter, 1981) .
NCS-382 antagonizes some effects of GHB including increases in cGMP levels
and inositol phosphate turnover in hippocampus, release of dopamine in striatum, and seizures in rats and mice (Maitre et al., 1990 Carai et al., 2001; Cook et al., 2002) ; the mechanism of this enhancement is not established. In the current study smaller doses of NCS-382 partially attenuated GHBlever responding; however, larger doses of NCS-382 failed to antagonize the discriminative stimulus effects of GHB and when these doses were studied alone they elicited considerable responding on the GHB-associated lever. Similarly under other conditions smaller doses of NCS-382 (25, 50 mg/kg) antagonized the discriminative stimulus effects of GHB whereas larger doses (300, 500 mg/kg) enhanced the sedative/hypnotic effects of GHB (Colombo et al., 1995; Schmidt-Mutter et al., 1998; Carai et al., 2001 ). These biphasic actions of NCS-382 further support the notion that the GHB discriminative stimulus comprises multiple mechanisms. The likelihood of obtaining antagonism of GHB with NCS-382 appears to depend on dose as well as behavioral endpoint since NCS-382 might be an antagonist at some receptors (e.g., GHB)
and an agonist at others (e.g., GABA).
GABA B receptors appear to play an important role in the discriminative stimulus effects of GHB. Baclofen occasioned greater than 84% GHB-lever responding in seven out of eight animals whereas the positive GABA A modulators diazepam and pregnanolone occasioned this level of responding in fewer animals (four of eight and four of seven, respectively) and only at doses that markedly decreased responding. The inability of flumazenil to antagonize the discriminative stimulus effects of GHB is consistent with GHB not binding to benzodiazepine receptors (Serra et al., 1991) . On the other hand, the selective GABA B receptor antagonist CGP 35348 attenuated GHB-lever responding occasioned by either baclofen or GHB, confirming the significant GABA B component in these effects of GHB.
This article has not been copyedited and formatted. The final version may differ from this version. (Snead, 1996) . GHB is less effective at displacing [ 3 H]GABA from GABA B receptors in the presence of the GHB dehydrogenase inhibitors valproate and ethosuximide (Hechler et al., 1997) , further indicating that GHB is metabolized to GABA to act at GABA B receptors. More recently (±)baclofen and GABA were shown to displace 20-30% of [ 3 H]NCS-382 binding in rat cerebral cortex (Mehta et al., 2001) . Further evidence that GHB can act directly at GABA B receptors was provided by Lingenhoehl et al. (1999) This study had several goals. First, stimulus control was established with GHB under conditions that are used widely in drug discrimination research and substitution data generated with this procedure support results from previous studies that used different parameters and subjects. The generality of the GHB stimulus, therefore, appears to extend across a range of experimental conditions. Second, the role of GABAergic, especially GABA B , systems was firmly established both by substitution of baclofen for GHB and, more importantly, by unequivocal antagonism of both baclofen and GHB by CGP 35348. Although GABA A systems might also contribute to these effects of GHB, their contribution is comparatively small. Third, results from this study strongly suggest that the inconsistent literature on NCS-382 with GHB is due to GHB, and possibly NCS-382, exerting effects through more than one mechanism. Finally, greater difficulty in obtaining GHB is thought to have stimulated increased recreational use of pharmacologically related compounds such as 1,4-BDL. This study demonstrates 
